References
- 1. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347:472-80.
- 2. Schwetz BA. New Treatment for Chronic Myelogenous Leukemia. JAMA. 2001; 286:35.
- 3. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002; 8: 935-42.
- 4. Ayoub WS, Geller SA, Tran T, Martin P, Vierling JM, Poordad FF. Imatinib (Gleevec®) induced hepatotoxicity. J Clin Gastroenterol 2005; 39:75-7.
- 5. Kikuchi S, Muroi K, Takahashi S, Kawano-Yamamoto C, Takatoku M, Miyazato A, et al. Severe hepatitis and complete molecular response caused by imatinib mesylate : possible association of its serum concentration with clinical outcomes. Leuk Lymphoma. 2004; 45:2349-51.
- 6. Lin NU, Sarantopoulos S, Stone JR, Galinsky I, Stone RM, Deangelo DJ, et al. Fatal hepatic necrosis following imatinib mesylate therapy. Blood. 2003; 102: 3455-6.
- 7. Ohyashiki K, Kuriyama Y, Nakajima A, Tauchi T, Ito Y, Miyazawa H, et al. Imatinib mesylate-induced hepatotoxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis, Leukemia. 2002; 16:2160-1.
- 8. James C, Trouette H, Marit G, Cony-Makhoul P, Mahon FX. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia. 2003; 7:978-9.
- 9. Pas TDe, Danesi R, Catania C, Curigliano G, Braud FDe. Imatinib administration in two patients with liver metastases from GIST and severe jaundice. Br J Cancer. 2003; 89:1403-4.
- 10. Bauer S, Hagen V, Pielken HJ, Bojko P, Seeber S, Schutte J. Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function. Anti-Cancer Drugs. 2002; 13:847-9.